(GNFT) Genfit S.A. - Ratings and Ratios
Elafibranor, NIS4, GNS561, VS-01, NASHnext
Description: GNFT Genfit S.A. October 29, 2025
Genfit S.A. (NASDAQ: GNFT) is a late-stage French biopharma focused on metabolic and liver diseases, operating a pipeline that spans small-molecule therapeutics and blood-based diagnostics. Its lead asset, Elafibranor, is in a Phase III trial for primary biliary cholangitis (PBC), while the company is also advancing NIS4 (a non-invasive NASH diagnostic), VS-01 (UCD/OAD therapy), GNS561 (cholangiocarcinoma), and several pre-clinical candidates targeting acute-on-chronic liver failure and hyperammonemia.
Key commercial partnerships include a licensing deal with Labcorp to market the NASHnext blood test and an agreement with Genoscience Pharma to co-develop GNS561 for cholangiocarcinoma. As of the most recent 10-Q, Genfit reported cash and cash equivalents of €115 million, giving it roughly 12-month runway assuming current burn rates, and its R&D spend has risen 18 % YoY, reflecting the acceleration of Phase III and Phase I/II studies.
From a market perspective, the global NASH therapeutic market is projected to exceed $30 billion by 2030, driven by rising obesity rates and limited approved treatments-factors that could amplify the upside of a successful Elafibranor or NASHnext launch. However, Phase III data for Elafibranor have shown mixed efficacy signals in prior interim analyses, introducing regulatory and commercial risk that must be weighed against the sizable unmet need.
For a deeper, data-driven assessment of GNFT’s valuation dynamics and scenario analysis, you may find the independent research platform ValueRay worth exploring.
GNFT Stock Overview
| Market Cap in USD | 215m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 2006-12-19 |
GNFT Stock Ratings
| Growth Rating | -9.29% |
| Fundamental | 17.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -44.3% |
| Analyst Rating | - |
GNFT Dividends
Currently no dividends paidGNFT Growth Ratios
| Growth Correlation 3m | 8.7% |
| Growth Correlation 12m | -15.3% |
| Growth Correlation 5y | -6.7% |
| CAGR 5y | -0.31% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.01 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.01 |
| Sharpe Ratio 12m | -1.07 |
| Alpha | -51.32 |
| Beta | 1.333 |
| Volatility | 37.13% |
| Current Volume | 146.4k |
| Average Volume 20d | 146.4k |
| Stop Loss | 3.2 (-6.4%) |
| Signal | -0.37 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-16.5m TTM) > 0 and > 6% of Revenue (6% = 7.23m TTM) |
| FCFTA -0.22 (>2.0%) and ΔFCFTA 9.28pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 94.49% (prev 365.9%; Δ -271.5pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.21 (>3.0%) and CFO -45.3m <= Net Income -16.5m (YES >=105%, WARN >=100%) |
| Net Debt (31.4m) to EBITDA (1.39m) ratio: 22.54 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.74 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (49.8m) change vs 12m ago 0.17% (target <= -2.0% for YES) |
| Gross Margin -6.00% (prev -98.49%; Δ 92.49pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 61.70% (prev 11.73%; Δ 49.97pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -0.26 (EBITDA TTM 1.39m / Interest Expense TTM 7.12m) >= 6 (WARN >= 3) |
Altman Z'' -5.10
| (A) 0.53 = (Total Current Assets 155.4m - Total Current Liabilities 41.6m) / Total Assets 216.7m |
| (B) -1.84 = Retained Earnings (Balance) -399.4m / Total Assets 216.7m |
| warn (B) unusual magnitude: -1.84 — check mapping/units |
| (C) -0.01 = EBIT TTM -1.85m / Avg Total Assets 195.3m |
| (D) -2.35 = Book Value of Equity -386.7m / Total Liabilities 164.2m |
| Total Rating: -5.10 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 17.58
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -21.64% = -5.0 |
| 3. FCF Margin -39.14% = -7.50 |
| 4. Debt/Equity 2.65 = -0.23 |
| 5. Debt/Ebitda 22.54 = -2.50 |
| 6. ROIC - WACC (= -8.07)% = -10.09 |
| 7. RoE -22.98% = -2.50 |
| 8. Rev. Trend 5.52% = 0.41 |
| 9. EPS Trend -30.26% = -1.51 |
What is the price of GNFT shares?
Over the past week, the price has changed by -5.36%, over one month by -0.06%, over three months by +2.58% and over the past year by -36.47%.
Is Genfit S.A. a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GNFT is around 3.08 EUR . This means that GNFT is currently overvalued and has a potential downside of -9.94%.
Is GNFT a buy, sell or hold?
What are the forecasts/targets for the GNFT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8.7 | 153.8% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 3.4 | -1.2% |
GNFT Fundamental Data Overview January 01, 1970
Market Cap EUR = 186.5m (186.5m EUR * 1.0 EUR.EUR)
P/E Forward = 7.5472
P/S = 4.1332
P/B = 3.3353
Beta = 1.333
Revenue TTM = 120.5m EUR
EBIT TTM = -1.85m EUR
EBITDA TTM = 1.39m EUR
Long Term Debt = 1.22m EUR (from longTermDebt, last quarter)
Short Term Debt = 17.6m EUR (from shortTermDebt, last quarter)
Debt = 138.9m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 31.4m EUR (from netDebt column, last quarter)
Enterprise Value = 217.9m EUR (186.5m + Debt 138.9m - CCE 107.5m)
Interest Coverage Ratio = -0.26 (Ebit TTM -1.85m / Interest Expense TTM 7.12m)
FCF Yield = -21.64% (FCF TTM -47.2m / Enterprise Value 217.9m)
FCF Margin = -39.14% (FCF TTM -47.2m / Revenue TTM 120.5m)
Net Margin = -13.68% (Net Income TTM -16.5m / Revenue TTM 120.5m)
Gross Margin = -6.00% ((Revenue TTM 120.5m - Cost of Revenue TTM 127.7m) / Revenue TTM)
Gross Margin QoQ = 0.21% (prev -281.0%)
Tobins Q-Ratio = 1.01 (Enterprise Value 217.9m / Total Assets 216.7m)
Interest Expense / Debt = 1.72% (Interest Expense 2.40m / Debt 138.9m)
Taxrate = 21.54% (-2.18m / -10.1m)
NOPAT = -1.45m (EBIT -1.85m * (1 - 21.54%)) [loss with tax shield]
Current Ratio = 3.74 (Total Current Assets 155.4m / Total Current Liabilities 41.6m)
Debt / Equity = 2.65 (Debt 138.9m / totalStockholderEquity, last quarter 52.5m)
Debt / EBITDA = 22.54 (Net Debt 31.4m / EBITDA 1.39m)
Debt / FCF = -0.67 (negative FCF - burning cash) (Net Debt 31.4m / FCF TTM -47.2m)
Total Stockholder Equity = 71.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.61% (Net Income -16.5m / Total Assets 216.7m)
RoE = -22.98% (Net Income TTM -16.5m / Total Stockholder Equity 71.8m)
RoCE = -2.54% (EBIT -1.85m / Capital Employed (Equity 71.8m + L.T.Debt 1.22m))
RoIC = -1.23% (negative operating profit) (NOPAT -1.45m / Invested Capital 118.3m)
WACC = 6.84% (E(186.5m)/V(325.4m) * Re(10.93%) + D(138.9m)/V(325.4m) * Rd(1.72%) * (1-Tc(0.22)))
Discount Rate = 10.93% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.08%
Fair Price DCF = unknown (Cash Flow -47.2m)
EPS Correlation: -30.26 | EPS CAGR: -28.56% | SUE: 0.0 | # QB: 0
Revenue Correlation: 5.52 | Revenue CAGR: -30.30% | SUE: N/A | # QB: 0